Nelmastobart is under clinical development by Stcube and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nelmastobart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nelmastobart overview

Nelmastobart (STT-003) is under development for the treatment of head and neck cancer, melanoma, colorectal cancer and colon cancer, non-small cell lung cance, small-cell lung cancer, transitional cell cancer (urothelial cell cancer), breast cancer, bile duct cancer (cholangiocarcinoma), ovarian cancer, pancreatic cancer, adrenocortical carcinoma (adrenal cortex cancer), anal cancer, esophageal cancer, skin cancer, thymic carcinoma . It acts by targeting BTN1A1. It is administered through intravenous route.

Stcube overview

Stcube is a developer and supplier of biopharmaceuticals. The company develops innovative bio-new drugs such as anti-cancer immunotherapies, immune checkpoint inhibitors, antibodies and small molecule compound treatments. STCube’s pipeline products include STT-001, STT-002, STT-005, SST-003, STT-011, STT-012, STT-013. It also caters to IT distribution businesses such as industrial LENS, small LCD monitors and printers. The company collaborates with academic, industrial, and clinical institutions. STCube is headquartered in Seoul, South Korea.

For a complete picture of Nelmastobart’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.